Insider · CIK 0001492749
Laurence Reid
Files at KALV (KalVista Pharmaceuticals, Inc.), MGX (Metagenomi Therapeutics, Inc.). First filing Sep 11, 2026, latest Sep 11, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MGX: Metagenomi Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | MGXbuy Metagenomi Therapeutics, Inc. | $23k 20,000 shares | - | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | MGX Metagenomi Therapeutics, Inc. | POpen-market purchase Common Stock | +19,883 | $1.17 | $23k | 19,883 | 32 d ago |
| Sep 9, 2026 | MGX Metagenomi Therapeutics, Inc. | POpen-market purchase Common Stock | +117 | $1.18 | $138 | 20,000 | 32 d ago |
| Sep 2, 2025 | MGX Metagenomi Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +42,000 | $0.00 | $0 | 42,000 | Sep 2, 2025 |
| Nov 23, 2024 | KALV KalVista Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,000 | $0.00 | $0 | 17,000 | Nov 26, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.